| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 17,310 | 17,840 | 17:07 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.10. | Earnings Call: XVIVO wächst im 3. Quartal 2026 kräftig - Markteinführung des Herztransplantationssystems schreitet voran | 11 | Investing.com Deutsch | ||
| 22.10. | Xvivo Perfusion AB Q3 Income Climbs | 2 | RTTNews | ||
| 22.10. | Xvivo Perfusion AB: Interim Report January - September 2026 | 187 | GlobeNewswire (Europe) | Third quarter 2026 (Jul-Sep)• Net sales amounted to SEK 252.6 million (189.1), corresponding to a growth of 34 percent in SEK.• Organic growth was 32 percent in local currencies. Excluding revenue from... ► Artikel lesen | |
| 14.10. | XVIVO Perfusion AB: Conference call on Interim Report July-September 2026 | 347 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / October 14, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report July-September 2026.... ► Artikel lesen | |
| 30.09. | Nomination Committee of XVIVO Perfusion AB | 374 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / September 30, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - The following members have been appointed to XVIVO Perfusion's nomination committee for the... ► Artikel lesen | |
| 28.09. | XVIVO Perfusion AB: XVIVO Announces FDA Receipt of PMA Application for The XVIVO Heart Assist Transport System | 2.607 | ACCESS Newswire | CAUTION-Investigational device in the US. Limited by Federal (United States) law to investigational use. The safety and effectiveness of this device have not been established. The XVIVO heart technology... ► Artikel lesen | |
| 20.08. | XVIVO erhält CE-Zertifikate für bahnbrechende Technologie zur Herzkonservierung | 13.479 | news aktuell | Göteborg/Berlin (ots) - - Die CE-Zertifizierungen ermöglichen den breiteren Einsatz der innovativen XVIVO-Technologie und verbessert den Zugang zu Herztransplantationen in Europa. XVIVO gibt die CE-Zertifizierungen... ► Artikel lesen | |
| 11.08. | Xvivo Perfusion AB: XVIVO receives CE certificates for its groundbreaking heart preservation technology, transforming access to life-saving transplants across Europe | 1.016 | GlobeNewswire (Europe) | CAUTION-Investigational device in the US. Limited by Federal (United States) law to investigational use. The safety and effectiveness of this device have not been established. The XVIVO heart technology... ► Artikel lesen | |
| XVIVO PERFUSION Aktie jetzt für 0€ handeln | |||||
| 03.08. | XVIVO Perfusion AB: XVIVO Granted Additional Patient Enrollment in the US PRESERVE CAP Study for XVIVO Heart Assist Transport | 478 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / August 3, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - XVIVO announces that the US Food and Drug Administration (FDA) has granted the company approval... ► Artikel lesen | |
| 14.07. | Xvivo Perfusion AB (publ) reports Q2 results | 3 | Seeking Alpha | ||
| 14.07. | Xvivo Perfusion AB Q2 Profit Rises | 3 | RTTNews | ||
| 14.07. | XVIVO übertrifft im Q2 die Umsatzerwartungen dank starkem Thorax-Geschäft | 2 | Investing.com Deutsch | ||
| 14.07. | XVIVO Perfusion AB: Interim Report January - June 2026 | 698 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 14, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Second quarter 2026 (Apr-Jun)Net sales amounted to SEK 239.0 million (178.3), corresponding to a growth... ► Artikel lesen | |
| 09.07. | OneLegacy Partners with XVIVO and Perfusion Solution to Launch the First Ex Vivo Lung Perfusion (EVLP) Center in the Western U.S. | 511 | Business Wire | OneLegacy, the nonprofit organ procurement organization serving Southern California, announced the launch of the first in-house Ex Vivo Lung Perfusion (EVLP) program at an organ procurement organization... ► Artikel lesen | |
| 26.06. | XVIVO Perfusion AB: Conference call on Interim Report April-June 2026 | 549 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / June 26, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report April-June 2026. The... ► Artikel lesen | |
| 18.05. | XVIVO Perfusion AB: Regulatory Derogation and Reimbursement in France Enable Life-Saving Use of XVIVO's Heart Technology | 464 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / May 18, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Hôpital La Pitié-Salpêtrière (Sorbonne University) in Paris, France, has, since the approval of... ► Artikel lesen | |
| 27.04. | Bulletin from Annual General Meeting in XVIVO Perfusion AB | 385 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 27, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV):The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion... ► Artikel lesen | |
| 24.04. | XVIVO Perfusion AB: Interim Report January - March 2026 | 276 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 24, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2026 (Jan-Mar)Net sales amounted to SEK 241.0 million (218.6), corresponding to growth... ► Artikel lesen | |
| 24.04. | Xvivo Perfusion AB: Interim Report January - March 2026 | 323 | GlobeNewswire (Europe) | First quarter 2026 (Jan-Mar)• Net sales amounted to SEK 241.0 million (218.6), corresponding to growth of 10 percent in SEK.• Organic growth was 23 percent in local currencies. Excluding revenue from... ► Artikel lesen | |
| 22.04. | XVIVO Perfusion AB: XVIVO Presents Encouraging Results From First Clinical Trial Using Hypothermic Oxygenated Perfusion In Direct Procurement DCD Heart Transplantation | 603 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 22, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, the results from the HOPE-at-Heart clinical trial (NCT06485596) were presented at the ISHLT... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 14,560 | -1,29 % | Eckert & Ziegler Aktie: Isotopen-Boom lässt Analysten aufhorchen | Die starke Nachfrage nach radioaktiven Isotopen für die Krebstherapie sorgt bei Eckert & Ziegler für steigende Gewinne und positive Analystenstimmen. Berenberg erhöht nach den Quartalszahlen das Kursziel... ► Artikel lesen | |
| INTUITIVE SURGICAL | 368,40 | -0,69 % | INTUITIVE SURGICAL INC - S-8, Securities to be offered to employees in employee benefit plans | ||
| RHOEN-KLINIKUM | 14,300 | -1,38 % | EQS-News: RHÖN-KLINIKUM Aktiengesellschaft: Befreiung nach § 37 Abs. 1 und Abs. 2 WpÜG i.V.m. § 9 Satz 1 Nr. 1 WpÜG-AngebVO von den Pflichten nach § 35 Abs. 1 Satz 1, § 35 Abs. 2 Satz 1 WpÜG in Bezug auf die RHÖN-KLINIKUM ... | EQS-News: RHÖN-KLINIKUM Aktiengesellschaft
/ Schlagwort(e): Sonstiges
Befreiung nach § 37 Abs. 1 und Abs. 2 WpÜG i.V.m. § 9 Satz 1 Nr. 1 WpÜG-AngebVO von den Pflichten nach §... ► Artikel lesen | |
| BICO GROUP | 1,376 | -2,41 % | BICO Group AB reports Q3 results | ||
| EUROFINS SCIENTIFIC | 84,92 | 0,00 % | Eurofins Scientific SE: Weekly Report on Share Repurchases from 09th November to 13th November 2026 | Regulatory News:
Eurofins Scientific SE (Paris:ERF):
Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument ... ► Artikel lesen | |
| M1 KLINIKEN | 18,180 | +3,53 % | EQS-Adhoc: M1 Kliniken AG: M1 Kliniken plant für 2027 den Wechsel in den Prime Standard und hebt das EBIT-Margenziel im Beauty-Segment auf mindestens 25 % an | EQS-Ad-hoc: M1 Kliniken AG / Schlagwort(e): Strategische Unternehmensentscheidung/Prognose / Sonstige
M1 Kliniken AG plant für 2027 den Wechsel in den Prime Standard und... ► Artikel lesen | |
| BAXTER | 23,600 | +2,03 % | BAXTER INTERNATIONAL INC - 8-K, Current Report | ||
| ASENSUS SURGICAL | - | - | Karl Storz to fully integrate Asensus, discontinue Senhance, Luna robots | ||
| JD HEALTH INTERNATIONAL | 3,689 | +2,93 % | Nomura Cuts JD HEALTH TP to HKD51; 4Q Revenue Outlook Weakens but Margin Expansion May Persist | ||
| COOPER COMPANIES | 54,24 | -2,11 % | Weltindex: MSCI World: Mindestens 28 Aktien müssen gehen, nur 2 neu kommen | © Foto: Zacharie Scheurer - dpa-tmnZum 30. November ändert MSCI den MSCI World: Mindestens 28 Aktien müssen gehen, nur Moderna und Aritzia kommen neu hinzu. Was ETF-Sparer jetzt wissen müssen und warum... ► Artikel lesen | |
| LIFEWARD | 2,950 | +0,68 % | Lifeward GAAP EPS of -$1.32 misses by $0.50, revenue of $5.43M misses by $1.81M | ||
| BONESUPPORT | 28,740 | +0,21 % | Bonesupport Holding AB: BONESUPPORT HOLDING AB (publ) - publishes Q3 2026 interim report | BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the third quarter 2026.
"Strong growth and important progress... ► Artikel lesen | |
| NATERA | 254,40 | -3,71 % | AI Takes On Cancer Detection From a Single Blood Draw (MEDS, ANT, GH, GRAL, NTRA, FRNM) | ||
| NANO-X IMAGING | 0,226 | -1,69 % | NANO-X IMAGING LTD: Nanox to Showcase Its Innovative Technology and Advances Across Nanox.ARC X and Nanox.AI at RSNA 2026 | ||
| SURGICAL SCIENCE SWEDEN | 5,450 | 0,00 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen |